Kazia Therapeutics (NASDAQ:KZIA) on Wednesday reported preliminary results from the first patient in its Phase 1b trial ...

A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

New publication in Nature Genetics using Parsortix identifies CTC clusters as promising targets to stop the spread of cancer ...

Stott et al. tested the CTC-chip for isolating and characterizing CTCs in patients with localized and metastatic prostate cancer.

The early data is particularly significant because CTC clusters are known to be critical mediators of metastasis and markers of poor prognosis. According to Kazia, standard chemotherapy often ...

The global Liquid Biopsy Market is valued at USD 11.41 Billion in 2024 and is projected to reach a value of USD 30.65 Billion ...

Circulating tumor cells (CTCs), which are tumor cells released into the bloodstream from primary neoplastic sites, offer a promising avenue for non-invasive cancer diagnostics.

Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) saw its stock jump 45% after unveiling preliminary data from the first patient ...

Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, today ...

ANGLE plc celebrates 100 peer-reviewed studies validating its Parsortix® system, enhancing cancer diagnostics and personalised treatment strategies.